Krystal Biotech Announces Positive Clinical Data for New Dermatology Program KB113 Demonstrating Broad Basal Cell Carcinoma Regression in Patients with Gorlin Syndrome
Globe Newswire•15/10/2026•07:00 ET
0
Key Highlights
- ➤KB113 produced clinical regression in 69 of 83 assessed lesions across three Gorlin syndrome patients
- ➤Non-injected lesions showed 85.1% regression, supporting a potential abscopal effect
- ➤Three biopsied injected lesions achieved histologically confirmed complete responses with no residual tumor
- ➤All KB113 adverse events were mild or moderate, transient, and resolved during the study
- ➤Krystal initiated FDA discussions on advanced KB113 development for Gorlin syndrome
Expert Statements
Shireen V. Guide, MD, Mission Dermatology Center
“For individuals living with Gorlin syndrome, the lifelong emergence of multiple BCCs creates an immense cumulative treatment burden—often resulting in extensive scarring and significant impacts on quality of life,”
Shireen V. Guide, MD, Mission Dermatology Center
“The observed antitumor responses with KB113 across both injected and non-injected lesions represent encouraging preliminary findings that strongly support its continued clinical development.”
Suma Krishnan, President of Research and Development at Krystal Biotech
“The breadth and depth of responses reported today on landmark lesions located in various parts of the patient’s body showcase the systemic immune-activating potential of HSV-1 encoded IL-2 and IL-12 and have exciting implications for Krystal and the many patients we aim to serve,”
Suma Krishnan, President of Research and Development at Krystal Biotech
“Leveraging our extensive HSV-1 dataset and clinical experience, we believe there is an opportunity to quickly advance our newly announced program for Gorlin syndrome and further our commitment to patients suffering from skin diseases.”
Over 80% of assessed basal cell carcinoma lesions regressed across three Gorlin syndrome patients treated with KB113
Substantial regression was observed in lesions not directly injected with KB113, consistent with abscopal effect
Get started
Create a free account to read the full story.